SPECIAL EMPHASIS PANELS
To view other meetings from ZAI1 choose calendar year:
| Study Section | Panel Name | Meeting Rosters |
|---|---|---|
| ZAI1 JHM-Z(M1) | NIAID SMALL BUSINESS: APPLIED IMMUNOLOGY AND VACCINE DEVELOPMENT | 05/14/25 |
| ZAI1 KLM-M(C1) | RESEARCH AREA 002: DEVELOPMENT OF DIRECT ACTING ANTIVIRALS (DAA) FOR VIRAL FAMILIES OF PANDEMIC POTENTIAL | 05/14/25 |
| ZAI1 LAR-Z(M1) | SMALL BUSINESS: ANTI-INFECTIVE AND IMMUNE DISEASE THERAPEUTICS | 05/13/25 |
| ZAI1 RCU-A(M1) | ENGINEERING DURABLE HIV VACCINE PROTECTION (ENDURE) (R01 CLINICAL TRIAL NOT ALLOWED) | 05/13/25 |
| ZAI1 LP-X(M2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 05/08/25 |
| ZAI1 LP-Z(M1) | NIH SUPPORT FOR CONFERENCES AND SCIENTIFIC MEETINGS (PARENT R13 CLINICAL TRIAL NOT ALLOWED) | 05/05/25 |
| ZAI1 PP-A(M1) | NOTICE OF SPECIAL INTEREST (NOSI): RESOURCE-RELATED RESEARCH PROJECT (R24) APPLICATIONS TO SUPPORT COLLABORATIVE IMPLEMENTATION SCIENCE TO END THE HIV EPIDEMIC AND NIAID RESOURCE RELATED RESEARCH PROJECTS (R24 CLINICAL TRIAL NOT ALLOWED) | 05/02/25 |
| ZAI1 LP-M(C1) | HHS-NIH-CDC-SBIR PHS 2025-1, PHASE I/II: DEVELOPMENT OF MEDICAL INTERVENTIONS FOR TREATING NON-TUBERCULOSIS MYCOBACTERIAL (NTM) INFECTIONS (TOPIC 144) | 05/02/25 |
| ZAI1 VSR-X(M3) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 05/01/25 |
| ZAI1 PT-I(C2) | NIAID CLINICAL PRODUCTS CENTER (CPC) (N01) | 04/30/25 |
| ZAI1 ZL-Z(M1) | NIAID SBIR (R43/R44), STTR (R41/R42), AND SB1 GRANT: MICROBIAL DIAGNOSTICS, DETECTION, AND DECONTAMINATION | 04/30/25 |
| ZAI1 MSA-A(C1) | SBIR TOPIC #NIH/NIMH 003 (POINT-OF-CARE AND PHARMACY-BASED ANTIRETROVIRAL DRUG ADHERENCE ASSAYS) (N01) | 04/30/25 |
| ZAI1 SAG-A(M2) | STRATEGIES FOR ELIMINATING HIV PROTEINS (R01, R21 CLINICAL TRIAL NOT ALLOWED) | 04/30/25 |
| ZAI1 VSR-I(M1) | NOTICE OF SPECIAL INTEREST (NOSI): COMPETITIVE REVISION SUPPLEMENTS TO EXISTING T32 PROGRAMS TO INCLUDE INSTITUTIONAL RESEARCH TRAINING IN DATA SCIENCE FOR INFECTIOUS AND IMMUNE MEDIATED DISEASES | 04/28/25 |
| ZAI1 SPJ-A(M2) | LIMITED COMPETITION: REVISION APPLICATIONS OF EXISTING NIH CENTERS FOR AIDS RESEARCH (CFAR) AND DEVELOPMENTAL CENTERS FOR AIDS RESEARCH (D-CFAR) GRANTS (P30 CLINICAL TRIAL NOT ALLOWED) | 04/28/25 |
| ZAI1 SAS-M(M1) | HALTING TUBERCULOSIS (TB) TRANSMISSION (R01 CLINICAL TRIAL OPTIONAL) | 04/28/25 |
| ZAI1 VS-A(M1) | NIAID CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRIAL NOT ALLOWED); INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01 CLINICAL TRIAL REQUIRED); NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 04/28/25 |
| ZAI1 FDS-D(M1) | NIAID NEW INNOVATORS AWARDS (DP2 CLINICAL TRIAL NOT ALLOWED) | 04/24/25 |
| ZAI1 MFH-M(M1) | PARTNERSHIPS FOR THE DEVELOPMENT OF TOOLS TO ADVANCE THERAPEUTIC DISCOVERY FOR SELECT ANTIBIOTIC-RESISTANT GRAM-NEGATIVE BACTERIA (R01 CLINICAL TRIAL NOT ALLOWED) | 04/24/25 |
| ZAI1 SA-A(M1) | MECHANISMS OF INDUCING HIV IMMUNITY IN EARLY LIFE (MIEL) (U01 CLINICAL TRIAL NOT ALLOWED) | 04/24/25 |
| ZAI1 VS-A(C1) | HHS-NIH-CDC-SBIR PHS 2025-1 PHASE I AND FAST TRACK: RAPID DIAGNOSTIC ASSAYS FOR SELF-MONITORING OF ACUTE OR REBOUND HIV-1 INFECTION (TOPIC 139) | 04/24/25 |
| ZAI1 KLM-D(M1) | SUPPORT FOR RESEARCH EXCELLENCE (SURE) AWARD (R16) CLINICAL TRIAL NOT ALLOWED) AND SUPPORT FOR RESEARCH EXCELLENCE FIRST INDEPENDENT RESEARCH (SURE-FIRST) AWARD (R16 - CLINICAL TRIAL NOT ALLOWED) | 04/22/25 |
| ZAI1 SPJ-D(M4) | NIAID RESEARCH EDUCATION PROGRAM (R25 CLINICAL TRIAL NOT ALLOWED) | 04/22/25 |
| ZAI1 AM-I(C2) | IMMUNE EPITOPE DATABASE AND ANALYSIS PROGRAM | 04/22/25 |
| ZAI1 HSC-I(M1) | NOVEL APPROACHES FOR RADIATION BIODOSIMETRY AND MEDICAL COUNTERMEASURES DEVELOPMENT (R21 CLINICAL TRIAL NOT ALLOWED) | 04/21/25 |
| ZAI1 LP-M(C2) | SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROGRAM CONTRACT SOLICITATION (PHS 2023-1) TOPIC 119 - ADAPTATION OF CRISPR-BASED IN VITRO DIAGNOSTICS FOR RAPID DETECTION OF SELECT EUKARYOTIC PATHOGENS | 04/21/25 |
| ZAI1 SA-A(C1) | HHS-NIH-CDC-SBIR PHS 2025-1 PHASE I AND FAST TRACK : DEVICES AND MATERIALS-BASED PLATFORMS FOR THE DELIVERY OF BROADLY NEUTRALIZING ANTIBODIES (TOPIC 138) | 04/21/25 |
| ZAI1 VSR-I(M2) | ALLERGY, IMMUNOLOGY, AND TRANSPLANTATION RESEARCH COMMITTEE (AITC) SPECIAL EMPHASIS PANEL | 04/18/25 |
| ZAI1 LG-M(M3) | NIAID CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRIAL NOT ALLOWED); NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED); NIAID SBIR PHASE II CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U44 CLI | 04/18/25 |
| ZAI1 MR-I(M2) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 04/17/25 |
| ZAI1 MSA-A(C2) | SBIR TOPIC #NIH/NIMH 004 (DEVELOPMENT OF NOVEL IN-VITRO AND IN-VIVO MODELS TO SUPPORT NEUROHIV RESEARCH) (N01) | 04/17/25 |
| ZAI1 SPJ-A(M3) | RUTH L. KIRSCHSTEIN NATIONAL RESEARCH SERVICE AWARD (NRSA) INSTITUTIONAL RESEARCH TRAINING GRANT (PARENT T32); HIV/AIDS SCHOLARS USING NONHUMAN PRIMATE (NHP) MODELS PROGRAM (K01 INDEPENDENT CLINICAL TRIAL NOT ALLOWED) | 04/17/25 |
| ZAI1 DF-M(C1) | HHS-NIH-CDC-SBIR PHS 2025-1 DEVELOPMENT OF DIAGNOSTICS FOR MYCOPLASMA GENITALIUM INFECTION (TOPIC 143) | 04/14/25 |
| ZAI1 BJM-A(M1) | PLANNING FOR PRODUCT DEVELOPMENT STRATEGY (R34 CLINICAL TRIAL NOT ALLOWED) | 04/14/25 |
| ZAI1 TCB-I(M3) | NIAID CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRIAL NOT ALLOWED) | 04/10/25 |
| ZAI1 LG-M(M2) | NIAID CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRIAL NOT ALLOWED); NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED); NIAID SBIR PHASE II CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U44 CLI | 04/09/25 |
| ZAI1 MR-I(M4) | NIAID RESOURCE RELATED RESEARCH PROJECTS (R24 CLINICAL TRIAL NOT ALLOWED) | 04/09/25 |
| ZAI1 MN-M(M2) | PROMOTING INNOVATIVE RESEARCH IN TREPONEMA PALLIDUM PATHOGENESIS (R21 CLINICAL TRIAL NOT ALLOWED) | 04/08/25 |
| ZAI1 LG-M(M1) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 04/07/25 |
| ZAI1 MR-I(M3) | NIAID RESOURCE RELATED RESEARCH PROJECTS (R24 CLINICAL TRIAL NOT ALLOWED) | 04/04/25 |
| ZAI1 JTS-I(M1) | IMMUNOBIOLOGY OF XENOTRANSPLANTATION (U01, U19 CLINICAL TRIAL NOT ALLOWED) | 04/03/25 |
| ZAI1 MMO-I(C1) | A SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FOR SMALL BUSINESS INNOVATION RESEARCH (SBIR) CONTRACT PROPOSALS (PHS 2025-1), NIH/NIAID 142 - ADJUVANT DEVELOPMENT FOR VACCI | 04/03/25 |
| ZAI1 MMO-I(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: ADJUVANT DEVELOPMENT FOR VACCINES FOR INFECTIOUS AND IMMUNE-MEDIATED DISEASES (TOPIC 128) | 04/03/25 |
| ZAI1 TCB-I(M1) | NIAID CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRIAL NOT ALLOWED) AND INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01 CLINICAL TRIAL REQUIRED) | 04/02/25 |
| ZAI1 TCB-I(M2) | NIAID SBIR PHASE II CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U44 CLINICAL TRIAL REQUIRED) | 04/02/25 |
| ZAI1 MN-M(M1) | INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01 CLINICAL TRIAL REQUIRED) AND NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 02/12/25 |
| ZAI1 MFH-M(M2) | NIAID CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRIAL NOT ALLOWED); NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 02/11/25 |
| ZAI1 SAG-M(M1) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 02/07/25 |
| ZAI1 AM-I(C1) | HHS-NIH-CDC-SBIR PHS 2025-1 PHASE I AND PHASE II: ADJUVANT DISCOVERY AND DOWN-SELECTION FOR VACCINES AGAINST INFECTIOUS AND IMMUNE-MEDIATED DISEASES (TOPIC 140) | 02/06/25 |
| ZAI1 MR-I(M1) | HUMAN LEUKOCYTE ANTIGEN (HLA) AND KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) REGION GENOMICS IN IMMUNE-MEDIATED DISEASES (U01 CLINICAL TRIAL NOT ALLOWED) | 02/05/25 |
| ZAI1 SB-I(C1) | HHS-NIH-CDC-SBIR PHS 2025-1 PHASE I: SOFTWARE OR WEB SERVICES TO ASSESS QUALITY AND REPRODUCIBILITY OF DATA AND INFORMATION ABOUT THERAPEUTICS AND VACCINES (TOPIC 147) | 02/05/25 |
| ZAI1 MC-M(C2) | HHS-NIH-CDC-SBIR PHS-2023-1 PHASE II: ADAPTATION OF CRISPR-BASED IN VITRO DIAGNOSTICS FOR RAPID DETECTION OF SELECT EUKARYOTIC PATHOGENS (TOPIC 119) | 02/04/25 |
| ZAI1 MC-M(C1) | HHS-NIH-CDC-SBIR PHS-2025-1 PHASE I AND II: DEVELOPMENT OF MEDICAL INTERVENTIONS FOR TREATING NON-TUBERCULOSIS MYCOBACTERIAL (NTM) INFECTIONS (TOPIC 144) | 02/03/25 |
| ZAI1 SPJ-D(M1) | NIAID RESEARCH EDUCATION PROGRAM (R25 CLINICAL TRIAL NOT ALLOWED) | 01/24/25 |
| ZAI1 BJM-A(C1) | A SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FOR SMALL BUSINESS INNOVATION RESEARCH (SBIR) CONTRACT PROPOSALS (PHS 2025-1), NIH/NIAID 137 - NEW DRUG CLASSES WITH NOVEL ME | 01/17/25 |
| ZAI1 KAR-M(C2) | HHS-NIH-CDC-SBIR PHS 2025-1 DISCOVERY AND DEVELOPMENT OF ORAL SMALL-MOLECULE DIRECT-ACTING ANTIVIRALS TARGETING VIRUSES OF PANDEMIC POTENTIAL (TOPIC 146) | 01/15/25 |
| ZAI1 PT-I(C1) | HHS-NIH-CDC-SBIR PHS 2025-1 PHASE I AND PHASE II: REAGENTS FOR IMMUNOLOGIC ANALYSIS OF NON-MAMMALIAN AND UNDERREPRESENTED MAMMALIAN MODELS (TOPIC 141) | 01/14/25 |
| ZAI1 KAR-M(C1) | HHS-NIH-CDC-SBIR PHS 2025-1 DIAGNOSTICS TO DETECT HOST IMMUNITY TO COCCIDIOIDOMYCOSIS (VALLEY FEVER) OR HISTOPLASMOSIS (TOPIC 145) | 01/09/25 |
| ZAI1 KAR-M(C4) | HHS-NIH-CDC-SBIR PHS 2023-1 PHASE II: ARTIFICIAL INTELLIGENCE TO IMPROVE CLINICAL MICROSCOPY FOR DIAGNOSIS OF INFECTIOUS DISEASES (TOPIC 121) | 01/07/25 |